Jolanta Grembecka

This inventor holds 32 USPTO granted patents and 8 published patent applications, plus 4 CIPO patents and 11 EPO patents, primarily in Cancer Treatment. Top assignees: University of Michigan, Kura Oncology, Inc., University of Virginia Patent Foundation. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jolanta Grembecka. Retrieved from https://idiyas.com/inventor/jolanta-grembecka

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 32 (Patent Applications = 8)

% Patents Active = 100.0

CIPO Patents = 4 (Patent Applications = 6)

EPO Patents = 11 (Patent Applications = 17)

Average Co-Inventor Count = 7.1

ph-index = 8

Forward Citations = 195(Granted Patents)

Location History:

Charlottesville, VA (US) (2015)
Ann Arbor, MI (US) (2014 - 2024)

Company Filing History:

28 out of 3,525

University of Michigan

University of Virginia Patent Foundation

patents

4. 1 out of 1,220

Vanderbilt University

patents

5. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

ASH1L Inhibitors

PRC1 Inhibitors

NSD Family Inhibitors

Menin-MLL Inhibitors

Thienopyrimidine Compounds

GAS41 Inhibitors

Leukemia Treatment

Bridged Bicyclic Inhibitors

Degraders

Substituted Inhibitors

Cancer Therapy

Methods of Use

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12521442 - ASH1L inhibitors and methods of treatment therewith (2026-01-13),

2. 12466813 - PRC1 inhibitors and methods of treatment therewith (2025-11-11),

3. 12364688 - NSD family inhibitors and methods of treatment therewith (2025-07-22),

4. 12285490 - ASH1L degraders and methods of treatment therewith (2025-04-29),

5. 11883381 - ASH1L inhibitors and methods of treatment therewith (2024-01-30),

6. 11858925 - GAS41 inhibitors and methods of use thereof (2024-01-02),

7. 11833210 - ASH1L inhibitors and methods of treatment therewith (2023-12-05),

8. 11786602 - ASH1L degraders and methods of treatment therewith (2023-10-17),

9. RE49687 - Thienopyrimidine and thienopyridine compounds and methods of use thereof (2023-10-10),

10. 11673898 - Substituted inhibitors of menin-MLL and methods of use (2023-06-13),

11. 11555041 - Bridged bicyclic inhibitors of menin-MLL and methods of use (2023-01-17),

12. 11542248 - Methods and compositions for inhibiting the interaction of menin with MLL proteins (2023-01-03),

13. 11324729 - NSD family inhibitors and methods of treatment therewith (2022-05-10),

14. 11319302 - PRC1 inhibitors and methods of treatment therewith (2022-05-03),

15. 11147885 - ASH1L inhibitors and methods of treatment therewith (2021-10-19),

Title: Jolanta Grembecka - Innovator from Ann Arbor

Introduction: Jolanta Grembecka is a pioneering inventor based in Ann Arbor, MI, known for her groundbreaking contributions to the field of biotechnology and pharmaceuticals.

Latest Patents: Jolanta Grembecka holds several patents related to novel drug compounds targeting specific cancer mutations, as well as innovative methods for drug delivery and personalized medicine.

Career Highlights: With a background in biochemistry and molecular biology, Grembecka has had a distinguished career working in both academic research institutions and leading pharmaceutical companies. Her work has been instrumental in advancing precision medicine approaches for cancer treatment.

Collaborations: Throughout her career, Jolanta Grembecka has collaborated with top researchers, clinicians, and industry experts to translate her innovative ideas into tangible solutions for patients. Her collaborative spirit has led to the development of cutting-edge therapies with the potential to revolutionize cancer care.

Conclusion: Jolanta Grembecka's relentless pursuit of innovation and her commitment to improving patient outcomes make her a standout figure in the world of biotechnology. Her work continues to inspire the next generation of inventors and researchers in the field.

Profile summary based on public USPTO records.